{"id":917169,"date":"2025-12-08T08:26:18","date_gmt":"2025-12-08T13:26:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/"},"modified":"2025-12-08T08:26:18","modified_gmt":"2025-12-08T13:26:18","slug":"cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/","title":{"rendered":"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Dec.  08, 2025  (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti\u2019s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025.<\/p>\n<p align=\"justify\">Details of the presentation can be found below.<\/p>\n<p>\n        <strong>Presenter:<\/strong> Mark Erlander, PhD (CEO) <br \/><strong>Date:<\/strong> 12\/11\/2025<br \/><strong>Time: <\/strong>4:00 PM ET<\/p>\n<p>Interested parties can register for and access the live webcast for the conferences by visiting the \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jq_jNLG3ZVR5vOAS5IvU1lcm5Q0MXolJuNK2PsmDwimqKxiugf5lOaVkc4gmuZeGeqXnRVx00SKs7-1bH3Sc-VRzPIrWlQtZe5sVTKXvV1XztUljKR7D5iZOOtaU5eWe\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.<\/p>\n<p>\n        <strong>About Cardiff Oncology, Inc. <\/strong><br \/>\n        <br \/>Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company&#8217;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtvxycFoEAM3AtKPxZRMtF5p5n8vApVtocrBaeADth3xqaWEHc4Kl2NaNm6tbHdVmBkcr6OtdETAW_LARvUcCg6qj6Z4d0qrDEIl99c2rIxQGXdUlGNBJFjxTRNZNw1Q\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cardiffoncology.com<\/a>.<\/p>\n<p>\n        <strong>Cardiff Oncology Contact: <\/strong><br \/>\n        <br \/>James Levine <br \/>Chief Financial Officer <br \/>858-952-7670 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=STPU6qH3CXvgjERaclqqwksnFeoeYqaEEW-RlmuiTjCQef7hVCKWdKDKMrew8BlZVKRIFUx0FCXY-PQKACYHnTiD7TkMVhFEcrwRMhRF1W1EkhSlWHzOSDde2utd93HT\" rel=\"nofollow\" target=\"_blank\">jlevine@cardiffoncology.com<\/a>\u00a0\u00a0<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Candice Masse<br \/>Astr Partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OMf8WpL8pgEwSQNC1ajgxUugy8Ycuahfw_PY6U7Zwq-40-ekH2k12BjEiWU9Kp4L9EfyIr3QtOeG2RTR-Qps8P34omlC8rr5JH_Ydy0EETv4DuuQycaoiFA0bt_MevQ1\" rel=\"nofollow\" target=\"_blank\">candice.masse@astrpartners.com<\/a>\u00a0\u00a0<\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <br \/>Amy Bonanno <br \/>Lyra Strategic Advisory <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5JmXW_aJjpTUbVYsAAMceOjLbPiH4PyxCrDRMrbQsUJtm-1AA-TZBxz7kXOdUJ5NRqzQsBsU7F7BnSLcxmxTA7_74v3w3q_URPy9SO_OOEodhEgAv0Nx-6JhwcLHnyfa\" rel=\"nofollow\" target=\"_blank\">abonanno@lyraadvisory.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzgxMjdjZjgtMWM4MS00YjRiLTg3ZDMtNDI1OTJiYjMyNzVlLTEyNjkwNTItMjAyNS0xMi0wOC1lbg==\/tiny\/Cardiff-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti\u2019s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12\/11\/2025Time: 4:00 PM ET Interested parties can register for and access the live webcast for the conferences by visiting the \u201cEvents\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917169","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti\u2019s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12\/11\/2025Time: 4:00 PM ET Interested parties can register for and access the live webcast for the conferences by visiting the \u201cEvents\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 &hellip; Continue reading &quot;Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T13:26:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference\",\"datePublished\":\"2025-12-08T13:26:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/\"},\"wordCount\":269,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/\",\"name\":\"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=\",\"datePublished\":\"2025-12-08T13:26:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference - Market Newsdesk","og_description":"SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) &#8212; Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti\u2019s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12\/11\/2025Time: 4:00 PM ET Interested parties can register for and access the live webcast for the conferences by visiting the \u201cEvents\u201d section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 &hellip; Continue reading \"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T13:26:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference","datePublished":"2025-12-08T13:26:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/"},"wordCount":269,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/","name":"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=","datePublished":"2025-12-08T13:26:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE4NSM3MzEwMTQwIzIyNTc1MDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-present-at-sidotis-year-end-virtual-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology to Present at Sidoti\u2019s Year-End Virtual Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917169"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917169\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}